SR 33805
SR 33805 用途与合成方法
|
L-type calcium channel 4.1 nM (EC 50 , in depolarized conditions) |
L-type calcium channel 33 nM (EC 50 , in polarized conditions) |
SR33805 (0.01-10 µM; 3 d) inhibits growth factor-induced proliferation of SMC (0.20
SR33805 (10 µM; 10 min) restores the myocardial infarction (MI)-altered cell shortening without affecting the Ca
2+
transient amplitude.
SR33805 (10 µM) decreases the activity of recombinant PKA.
Cell Viability Assay
| Cell Line: | Smooth muscle cells (SMC) |
| Concentration: | 0.01, 0.1, 1, 10 µM |
| Incubation Time: | 3 days |
| Result: | Inhibited in a dose-dependent manner FCS-, bFGF and PDGF-induced proliferation of porcine SMC with IC 50 s of 0.26±0.08, 0.46±0.1 and 0.20±0.04 µM, respectively. |
SR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats.
SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs.
| Animal Model: | Male Wistar rats (5 weeks) are subjected to coronary artery ligature |
| Dosage: | 0.2, 2, 20 mg/kg |
| Administration: | A single i.p. injection |
| Result: |
Increased significantly both end-systolic strain (ESS) and fractional shortening (FS) by about +38 and +26%, respectively at the dose of 20 mg/kg.
Did not affect other contractile parameters. |
SR 33805 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-136909 | 121345-64-0 | 1 mg | 410 | |
| 2026-09-15 | HY-136909 | SR 33805 | 121345-64-0 | 5mg | 1110 |
